Cercar
01/04/2024
SER recommendations on treatment of refractory Behc , et's syndrome
Morales, CM, Gil, JG, García, NB, Varillas, JLM, del Río, VC, Alvarado, PM, García, FJN, Espinosa, G, Fontecha, PDD, Rodríguez, MG, Arranz, JM, Gómez, ML, Hernández, FMF, Trujillo, MM, Sobrín, RD, Sánchez, JIM, Manzano, JM, Cuba, JS. SER recommendations on treatment of refractory Behc , et's syndrome. Reumatologia Clinica. 2024; 20(4)DOI:10.1016/j.reuma.2023.12.001. PMID:38614885. IF:(Q/D).
01/03/2024
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register
Fernández-Lozano, D, Hernández-Rodríguez, I, Narvaez, J, Domínguez-Alvaro, M, De Miguel, E, Silva-Díaz, M, Belzunegui, JM, Morales, CM, Sánchez, J, Galíndez-Agirregoikoa, E, Aldaroso, V, Abasolo, L, Loricera, J, Garrido-Puñal, N, Alvarado, PM, Larena, C, Navarro, VA, Calvet, J, Casafont-Solé, I, Ortiz-Sanjuán, F, Monte, TCS, Castañeda, S, Blanco, R. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register. RMD Open. 2024; 10(1)DOI:10.1136/rmdopen-2023-003824. PMID:38531620. IF:4.700(Q1/1D).
01/03/2024
Persistentsciatic artery, an uncommon cause of femoropopliteal occlusion
Casademont, EB, Molina, JM. Persistentsciatic artery, an uncommon cause of femoropopliteal occlusion. Angiologia. 2024; 76(2)DOI:10.20960/angiologia.00496. PMID:. IF:(Q/D).
26/02/2024
Prognostic significance of lymphocytic foci composition in minor salivary gland biopsies for severe disease flare and severity in Sjögren's syndrome: a 3-year follow-up cohort study
Park, HS, Martínez-Martínez, L, López, BM, Castellví, I, Moya, P, Codes-Mendez, H, Sosa, NH, Diaz-Torne, C, Laiz, A, Sainz, L, Tandaipan, JL, Mariscal, A, Franco-Leyva, T, Casademont, J, Juarez, C, Corominas, H. Prognostic significance of lymphocytic foci composition in minor salivary gland biopsies for severe disease flare and severity in Sjögren's syndrome: a 3-year follow-up cohort study. Frontiers in Immunology. 2024; 15DOI:10.3389/fimmu.2024.1332924. PMID:38469314. IF:5.900(Q1/2D).
01/02/2024
Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
Molina-Collada, J, Alonso, F, Otero, L, Bohórquez, C, Torné, CD, García, CP, Madrigal, JMB, Vela, P, Alvaro-Gracia, JM, Castrejón, I. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2024; 64DOI:10.1016/j.semarthrit.2023.152341. PMID:38128174. IF:4.400(Q1/1D).
01/02/2024
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
López-Medina, C, Calvo-Gutiérrez, J, Abalos-Aguilera, MC, Cepas, F, Plasencia-Rodríguez, C, Martínez-Feito, A, Balsa, A, Faré-García, R, Juan-Mas, A, Ruiz-Esquide, V, Sainz, L, Díaz-Torné, C, Godoy-Navarrete, FJ, Añón-Oñate, I, Mena-Vázquez, N, Manrique-Arija, S, Moreno-García, MS, Ortega-Castro, R, Escudero-Contreras, A. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024; 10(1)DOI:10.1136/rmdopen-2023-003975. PMID:38395455. IF:4.700(Q1/1D).